Susan Benton
CIK: 0001373649
Susan Benton's purchase track record
Susan Benton has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/2/2021 | IRD | $91K | -17.9% | -27.8% | -3.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| IRD | ▲ Buy | Grant | 24,367 | $0 | 4/20/2026 | View on chart |
| IRD | ▲ Buy | Grant | 79,504 | $0 | 4/30/2025 | View on chart |
| IRD | ▲ Buy | Grant | 41,143 | $0 | 6/11/2024 | View on chart |
| IRD | ▲ Buy | Grant | 19,418 | — | 1/1/2024 | View on chart |
| IRD | ▲ Buy | Grant | 10,976 | $0 | 6/6/2023 | View on chart |
| IRD | ▲ Buy | Grant | 1,053 | — | 4/19/2023 | View on chart |
| IRD | ▲ Buy | Grant | 16,267 | — | 1/11/2023 | View on chart |
| IRD | ▲ Buy | Grant | 12,376 | — | 7/1/2022 | View on chart |
| IRD | ▲ Buy | Grant | 6,335 | — | 7/1/2022 | View on chart |
| IRD | ▲ Buy | Grant | 3,395 | — | 4/1/2022 | View on chart |
| IRD | ▲ Buy | Grant | 2,949 | — | 1/3/2022 | View on chart |
| IRD | ▲ Buy | Grant | 2,135 | — | 10/1/2021 | View on chart |
| IRD | ▲ Buy | Open Market | 20,000 | $91K | 9/2/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 5, 2026
Opus Genetics to Present at Euretina 2026
Opus Genetics announced it will present data at the Euretina 2026 conference. This event is relevant as it provides a platform for the company to share scientific updates on its gene therapy programs. The stock currently trades below the average analyst target price, with a 52-week range spanning from $1.32 to $7.07.
Opus Genetics to Present at Euretina 2026. Opus Genetics announced it will present data at the Euretina 2026 conference. This event is relevant as it provides a platform for the company to share scientific updates on its gene therapy programs. The stock currently trades below the average analyst target price, with a 52-week range spanning from $1.32 to $7.07.